Abstract | BACKGROUND: CASE REPORT: CONCLUSION: A combination therapy including ICI is a promising treatment option for HCC with concurrent malignancies.
|
Authors | Hiroshi Aoki, Naoki Matsumoto, Hiroshi Takahashi, Masayuki Honda, Tomohiro Kaneko, Shuhei Arima, Tomotaka Ishii, Taku Mizutani, Ryota Masuzaki, Kazushige Nirei, Hiroaki Yamagami, Masahiro Ogawa, Tatsuo Kanda, Mitsuhiko Moriyama, Katsuhiro Miura |
Journal | Anticancer research
(Anticancer Res)
Vol. 41
Issue 12
Pg. 6225-6230
(Dec 2021)
ISSN: 1791-7530 [Electronic] Greece |
PMID | 34848477
(Publication Type: Case Reports, Journal Article)
|
Copyright | Copyright © 2021 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved. |
Chemical References |
- Immune Checkpoint Inhibitors
|
Topics |
- Aged
- Humans
- Immune Checkpoint Inhibitors
(pharmacology, therapeutic use)
- Male
- Middle Aged
- Neoplasm Metastasis
|